TY - JOUR
T1 - Angiosarcoma
T2 - a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies
AU - Luong, Huyen Thuc Tran
AU - Vercammen, Sofie
AU - de Marco, Ario
AU - de Rooster, Hilde
AU - Cosma, Antonio
N1 - Funding:
The author(s) declare that financial support was received for the
research and/or publication of this article. This research was funded
in whole, or in part, by the Luxembourg National Research Fund
(FNR), grant reference INTER/ARIS/23/17973671. For the purpose
of open access, and in fulfillment of the obligations arising from the
grant agreement, the author has applied a Creative Commons
Attribution 4.0 International (CC BY 4.0) license to any Author
Accepted Manuscript version arising from this submission. AM
was supported by the grant J4-50144 provided by the Javne
agencije za znanstveno-raziskovalno in inovacijsko dejavnost
Republike Slovenije. SV and HR were supported by the grant
FWO.OPR.2024.0077.01 - FWO WEAVE
Copyright © 2025 Luong, Vercammen, de Marco, de Rooster and Cosma.
PY - 2025/7/1
Y1 - 2025/7/1
N2 - Angiosarcoma is a rare, aggressive vascular malignancy characterized by rapid proliferation, early metastasis, and limited therapeutic options, resulting in poor prognosis. The etiopathogenesis of AS remains elusive and diagnosis is challenging due to its similarity to other vascular lesions. This systematic review aims to synthesize existing literature on biomarkers in human AS tissue, encompassing genomic alterations, metabolic pathway changes, specific protein, and their implications for diagnosis, prognosis, and therapy. Eighty-seven studies were identified as meeting predefined eligibility criteria following a systematic search of Pubmed and Embase between 1996 and 2024. The review highlights recurrent mutations (e.g., TP53, POT1, MYC, PTPRB, KDR), altered metabolic pathways (VEGF, ANGPT-TIE, PI3K/Akt/mTOR, MAPK/ERK), and diverse protein expression patterns (e.g., ERG, CD31, CD34, vWF). These biomarkers underscore the complex molecular landscape of AS and offer potential targets for improved diagnostic, prognostic, and therapeutic strategies. This review provides a foundation for further research and the development of novel diagnostic and therapeutic approaches for this challenging malignancy. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251019523, identifier (CRD420251019523).
AB - Angiosarcoma is a rare, aggressive vascular malignancy characterized by rapid proliferation, early metastasis, and limited therapeutic options, resulting in poor prognosis. The etiopathogenesis of AS remains elusive and diagnosis is challenging due to its similarity to other vascular lesions. This systematic review aims to synthesize existing literature on biomarkers in human AS tissue, encompassing genomic alterations, metabolic pathway changes, specific protein, and their implications for diagnosis, prognosis, and therapy. Eighty-seven studies were identified as meeting predefined eligibility criteria following a systematic search of Pubmed and Embase between 1996 and 2024. The review highlights recurrent mutations (e.g., TP53, POT1, MYC, PTPRB, KDR), altered metabolic pathways (VEGF, ANGPT-TIE, PI3K/Akt/mTOR, MAPK/ERK), and diverse protein expression patterns (e.g., ERG, CD31, CD34, vWF). These biomarkers underscore the complex molecular landscape of AS and offer potential targets for improved diagnostic, prognostic, and therapeutic strategies. This review provides a foundation for further research and the development of novel diagnostic and therapeutic approaches for this challenging malignancy. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251019523, identifier (CRD420251019523).
KW - angiosarcoma
KW - biomarkers
KW - diagnosis
KW - genetic alterations
KW - metabolic pathway
KW - prognosis
KW - protein
KW - therapeutic strategies
UR - https://www.scopus.com/pages/publications/105011648443
UR - https://pubmed.ncbi.nlm.nih.gov/40666093/
U2 - 10.3389/fonc.2025.1623327
DO - 10.3389/fonc.2025.1623327
M3 - Review article
C2 - 40666093
AN - SCOPUS:105011648443
SN - 2234-943X
VL - 15
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1623327
ER -